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Lipid profi les of patients presenting 
with acute myocardial infarction in 
a South African regional hospital
LIPID PROFILE IN 
MYOCARDIAL 
INFARCTION
least 10%, as well as reducing major cardiac events by 23% for 
every 1.0mmol/L reduction in LDL-C.(5) A lipid profile should 
be performed at the time of admission, together with the 
initiation of statin therapy. Lipid profiles should be repeated 
4 - 6 weeks after discharge. The South African Dyslipidaemia 
Guideline Consensus Statement (SADGCS) recommends a 
target LDL-C value less than 1.8mmol/L for subjects considered 
to be at very high risk of cardiovascular events.(5)
In this study we set out to determine the prevalence of hyper-
lipidaemia in subjects admitted with AMI to an urban regional 
hospital in KwaZulu-Natal, and to determine the association of 
lipid levels with previous statin therapy – thus estimating the 
extent to which hyperlipidaemia contributes to the incidence of 
AMI in our population.
INTRODUCTION
Cardiovascular disease (CVD) is 1 of the most frequent causes 
of death in developing and developed nations. In 2011, the 
World Health Organisation (WHO) estimated annual deaths 
from CVD at more than 17 million, of which 7.6 million were 
due to ischaemic heart disease resulting in an acute myocardial 
infarction (AMI).(1) In South Africa, CVD is the second most 
prevalent cause of death after HIV-associated disease, and 
accounts for up to 40% of deaths among adults.(2) 
AMI typically follows the rupture of an atherosclerotic plaque, 
with resultant platelet aggregation and thrombotic occlusion. 
Modifiable risk factors for atherosclerosis include hyperlipi-
daemia, smoking, hypertension, diabetes mellitus (DM), abdo-
minal obesity and physical inactivity.(3,4) These risk factors 
synergistically increase the overall risk of development of an 
AMI, regardless of gender or age.(5) Increased levels of low-
density lipoprotein cholesterol (LDL-C) and decreased levels 
of high-density lipoprotein cholesterol (HDL-C) play a pivotal 
role in atherogenesis and are associated with a higher risk of 
development of coronary artery disease (CAD).(6-8) 
Statin therapy has been implemented in both primary and 
secondary prevention of CAD.(9) Statin therapy following an 
AMI has been shown to be effective in reducing mortality by at 
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Background: Cardiovascular disease is an important 
cause of morbidity and mortality in South Africa and 
hyperlipidaemia is a major contributing modifi able risk 
factor. 
Objectives: To describe the lipid profi les of patients 
with acute myocardial infarction and to compare values 
with recommended target levels outlined in the South 
African Dyslipidaemia Guideline Consensus Statement.
Methods: We performed a retrospective chart review 
of patients admitted with a diagnosis of acute myocardial 
infarction to a regional hospital in Durban, South Africa, 
between 1 January and 31 December 2016. Patients had 
a non-fasting lipogram taken within the fi rst 24 hours of 
admission.
Results: We enrolled 126 subjects. The mean age was 
57.6 (SD ± 9.4) years. One hundred and ten subjects 
(87.3%) met criteria for hyperlipidaemia. Previous statin 
therapy was associated with lower LDL-cholesterol 
values (3.43mmol/L vs. 4.03mmol/L, p=0.02), but only 9 
(11.2%) of the 80 subjects on therapy (88.8%) fell below 
the levels recommended for their risk category by the 
South African Dyslipidaemia Guideline Consensus State-
ment. Overall, 23 subjects (18.3% of the entire study 
group) demonstrated LDL-C values at presentation that 
were below the recommended values.
Conclusions: A high proportion of subjects presenting 
with acute myocardial infarction show evidence of sub-
optimal control of pre-existing hyperlipidaemia.  
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The study site is a 350-bed regional hospital in Durban, 
KwaZulu-Natal, which services the communities of Phoenix, 
Inanda, Amaoti and Mount Edgecombe, with most of this 
population being represented by people of Indian and African 
descent. Patients with AMI are managed in the general medical 
ward as the hospital does not have critical care facilities.
We performed a retrospective chart review of all patients 
aged 18 years or older, admitted with an AMI from 1 January - 
31 December 2016. The diagnosis of AMI was based on a 
history of typical ischaemic chest pain, and elevated Troponin T 
levels, with or without typical electrocardiographic (ECG) 
changes. ST-elevation myocardial infarction (STEMI), was 
defined as the presence of significant ST elevations or new 
LBBB on ECG and non-ST-elevation myocardial infarction 
(NSTEMI) was defined as absence of ST elevation with or with-
out ST depression or T wave inversions. 
All patients had a non-fasting lipogram taken within the first 
24 hours of admission, which included total cholesterol (TC), 
HDL-C, triglycerides (TG) and calculated LDL-C. Patients 
were diagnosed with hyperlipidaemia if their TC exceeded 
5.0mmol/L, LDL-C values were more than 3.0mmol/L, and 
HDL-C less than 1.0mmol/L or 1.2mmol/L for males and 
females respectively. A target LDL-C value less than 1.8mmol/L 
was used for subjects considered to be at very high risk of 
cardiovascular events. For the purpose of this study, those 
subjects with abnormal lipid parameters (raised LDL-C, raised 
TC or low HDL-C) were further subclassif ied into mixed 
hyperlipidaemia (3 abnormal parameters), combined hyper-
lipidaemia (2 abnormal lipid parameters) and isolated (single 
parameter) hyperlipidaemia. 
Data on prevalence of risk factors were also documented. 
Premature CAD was defined as CAD diagnosed in males 
before 55 years of age and in females before 60 years, as per 
the SADGCS.(5) The target value for glycated haemoglobin 
(HbA1c) was less than 7%, as recommended by 2012 SEMDSA 
guidelines. 
Data was captured on a data collection sheet and collated 
using a Microsoft Excel® spreadsheet (Microsoft Office 2016, 
Microsoft Corporation, Redmond WA, USA). Statistical analysis 
was performed using Statistical Package for the Social Sciences 
(SPSS) version 24.0 (SPSS Statistics for Windows, IBM Corp., 
Armonk, NY) and MedCalc Statistical Software version 18.6 
(MedCalc Software bvba, Ostend, Belgium). Ethical clearance 
was obtained from the Biomedical Research Ethics Committee 
of the University of KwaZulu-Natal (authorisation BE:394/17). 
The hospital management of Mahatma Gandhi Memorial 
Hospital and the KwaZulu-Natal Department of Health pro-
vided the relevant permissions.
Continuous variables with a normal distribution are expressed 
as mean and standard deviation (± SD), and means are com-
pared using Student’s t test or ANOVA. Categorical variables 
were evaluated by chi-square or Fisher’s exact test. A two-
tailed p value <0.05 was considered statistically significant. 
RESULTS 
During the study period, 154 subjects presented to the emer-
gency department with a suspected diagnosis of AMI. Twenty 
eight were excluded, leaving a final sample of 126 subjects 
(Figure 1). The demographic profile, clinical presentation and 
risk profile of the subjects is shown in Table I. One hundred 
and nineteen subjects were of Indian descent and 7 of African 
descent. Females had a significantly higher incidence of pre-
mature CAD (81.3%) than males (38.5%, p<0.0001). Seventy 
seven (61.1%) subjects showed evidence of NSTEMI and 49 
(38.9%) showed evidence of STEMI.
The mean number of risk factors per subject was 3.45. Hyper-
tension and DM were significantly more prevalent in female 
subjects. The mean glycated haemoglobin (HbA1c) values of all 
tested subjects were significantly higher in females than in 
males. Females demonstrated significantly less association with 
smoking and family history of CAD than males. We did not 
demonstrate a significant difference between men and women 
for age, mean number of risk factors, prevalence of pre-
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vious acute coronary syndrome (ACS), or mean length of stay 
(Table I). Thirty one (24.6%) subjects had a previous AMI. 
In comparison with the subjects experiencing a first AMI, this 
group did not differ significantly in terms of gender, age, smoking 
history, hypertension or alcohol use (data not shown). They 
were, however, more likely to have a family history of CAD: 
24 of 31 (77.4%) vs. 51 of 95 (53.7%, p=0.02) and to have 
DM: 25 (80.6%) vs. 52 (54.7%, p=0.01).
We noted a high prevalence of combined and mixed hyper-
lipidaemia (Figure 2). The distribution of values for each lipo-
protein is shown in Table II. There were no statistically signifi-
cant differences in lipid profile between males and females. 
Eighty subjects had received prior therapy with either sim-
vastatin or atorvastatin (Table III). No subject was reported as 
having used fibrates or other lipid-lowering agents. We noted a 
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TABLE I: Demographics of the study population.
Parameter Males Females Total p value*
No. of subjects 78 (61.9%) 48 (38.1%) 126 0.008
Mean age (years) 57.5 (SD ± 8.99) 57.7 ( SD ± 10.4) 57.6 ( SD ± 9.4) 0.873
Premature CAD (presentation <60 years) 30 (38.5%) 39 (81.3%) 69 (54.8%) <0.0001
Ethnicity 0.593
Indian descent 73 (93.6%) 46 (95.8%) 119 (94.4%)
African descent 5 (6.4%) 2 (4.2%) 7 (5.6%)
Type of AMI  0.079
STEMI subtype 35 (44.9%) 14 (29.2%) 49 (38.9%) 0.074
NSTEMI subtype 43 (55.1%) 34 (70.8%) 77 (61.1%)
Risk Factors
Hyperlipidaemia 66 (60%) 44 (40%) 110 (87.3%) 0.248
Previously diagnosed 47 (58.8%) 33 (41.2%) 80 (63.5%)
New diagnosis 19 (63.3%) 11 (36.7%) 30 (23.8%)
Diabetes mellitus 42 (53.8%) 35 (72.9%) 77 (61.1%) 0.03
Mean HbA1c (%) 7.8 ( SD ± 2.2) 8.9 ( SD ± 2.6) 8.23 ( SD ± 2.5) 0.023
Hypertension 47 (60.3%) 40 (83.3%) 87 (69%) 0.007
Smoker 56 (71.8%) 7 (14.6%) 63 (50%) <0.0001
Family history of CAD 54 (69.2%) 21 (43.8%) 75 (59.5%) 0.005
Previous ACS 21 (26.9%) 10 (20.8%) 31 (24.6%) 0.041
Alcohol use 13 (16.7%) 1 (2.1%) 14 (11.1%) 0.011
Mean risk factors per patient 3.62 (1.36) 3.19 (1.36) 3.45 (1.37) 0.89
Mean LOS (days) 6.38 ( SD ± 1.54) 6.39 ( SD ± 1.60) 6.39 ( SD ± 1.55) 0.995
ACS = Acute coronary syndrome, AMI = Acute myocardial infarction, CAD = Coronary artery disease, LOS = Length of stay, NSTEMI = Non-ST elevation myocardial infarction, 
STEMI = ST elevation myocardial infarction, SD = Standard deviation. * Denotes p value when comparing males with females.
FIGURE 2: Distribution of lipid abnormalities. 
Isolated, combined and mixed hyperlipidaemia refers 
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TABLE II: Lipid profiles.
Lipid component Male (n=78) Female (n=48) Total (n=126) p value*
Total cholesterol (mmol/L) 5.19 ( SD ± 1.33) 5.50 ( SD ± 1.69) 5.31 ( SD ± 1.48) 0.266
LDL-C (mmol/L) 3.27 ( SD ± 1.19) 3.55 ( SD ± 1.50) 3.39 ( SD ± 1.32) 0.248
HDL-C (mmol/L) 0.99 ( SD ± 0.28) 1.10 ( SD ± 0.36) 1.03 ( SD ± 0.32) 0.053
Triglycerides (mmol/L) 2.08 ( SD ± 1.22) 2.20 ( SD ± 1.35) 2.13 ( SD ± 1.27) 0.602
Non-HDL-C (mmol/L) 4.20 ( SD ± 1.27) 4.51 ( SD ± 1.65) 4.32 ( SD ± 1.43) 0.248
Non-fasting lipid profiles performed within 24 hours of acute myocardial infarction. HDL-C = High-density lipoprotein cholesterol, LDL-C = Low-density lipoprotein cholesterol, 
SD = Standard deviation. *p value for significance of difference between male and female subjects.     
TABLE III: Effect of pre-existing statin therapy on observed lipid values and myocardial infarction.
Finding On statin therapy(n=80)
Not on statin therapy
(n=30) p value
*
Total cholesterol (mmol/L) 5.44 ( SD ± 1.45) 5.82 ( SD ± 1.29) 0.207
LDL-C (mmol/L) 3.43 ( SD ± 1.26) 4.03 ( SD ± 1.10) 0.023
HDL-C (mmol/L) 1.01 ( SD ± 0.31) 1.12 ( SD ± 0.38) 0.127
Triglycerides (mmol/L) 2.27 ( SD ± 1.34) 1.98 ( SD ± 1.09) 0.287
Non-HDL-C (mmol/L)  4.43 ( SD ± 1.37) 4.70 ( SD ± 1.17) 0.332
Mean number of lipid abnormalities 2.3 2.4 0.345
Premature CAD 51 (63.8%) 18 (60.0%) 0.717
Type of infarct 0.029
NSTEMI 53 (66.3%) 13 (43.3%)
STEMI 27 (33.8%) 17 (56.7%)
Admission troponin ng/L 3733 ( SD ± 26008) 3844 ( SD ± 13100) 0.982
Admission CPK u/L 646 ( SD ± 817) 1084 ( SD ± 1903) 0.094
LDL-C = Low-density lipoprotein cholesterol, HDL-C = High-density lipoprotein cholesterol, CAD = Coronary artery disease, NSTEMI = Non-ST elevation myocardial infarction, 
STEMI = ST-elevation myocardial infarction, CPK = Creatine phosphokinase, SD = Standard deviation. *Denotes p value when comparing pre-existing versus no pre-existing 
statin therapy.
significantly lower LDL-C and lower incidence of STEMI in 
those who had received statin therapy. There were no signifi-
cant differences in other lipid parameters between these 2 
groups. There was no signif icant difference in lipid levels 
between diabetic and non-diabetic subjects, and no significant 
correlation between lipid levels and the extent of diabetic 
control (Table IV). Poor lipid control was seen in subjects with 
both controlled and poorly controlled DM, as assessed by 
HbA1c levels. Diabetic patients were significantly more likely 
to demonstrate an NSTEMI.
The distribution of LDL-C values is shown in Figure 3, cate-
gorised by risk and by statin therapy. Few subjects, irrespective 
of risk category or of statin therapy, had LDL-C values below 
the SADGCS-recommended levels (Table V). No lipid para-
meter differed significantly between those subjects with a 
previous AMI and those with a first AMI (data not shown). 
There was no significant difference in the number of subjects 
with and without a previous AMI whose LDL-C value was 
below the target level recommended for their risk category, 
as defined above: 4 of 31 (12.9%) vs. 19 of 95 (20.0%, p=0.44). 
There was also no significant difference in the number of dia-
betic subjects with and without previous AMI with an optimal 




Nearly all subjects were of Indian descent. Though this is in 
keeping with previous studies showing South African Indian 
subjects to be a high-risk population for CAD, with a high 
prevalence of hyperlipidaemia,(10-12) the prevalence we found 
is likely to have been influenced by the surrounding population 
of our hospital, which serves an area with a large Indian popula-
tion. Most subjects in this study were shown to have hyper-
lipidaemia, with 63.5% having a pre-existing diagnosis of hyper-
lipidaemia and 23.8% subjects a new diagnosis (Table 1). 
Increased TC, LDL-C and non-HDL-C levels, with decreased 
levels of HDL-C, were seen in most subjects in this study – 
indicating poor lipid control. Elevated non-HDL-C may be a risk 
indicator for CVD and the mean level in our study population 
was 4.43, with the target value being less than 2.6mmol/L.(13) 
A large number of subjects previously diagnosed with hyper-
lipidaemia had poorly controlled lipid levels, despite being on 
statin therapy (Table V). Those treated with statins did show a 
significant reduction in LDL-C levels compared with untreated 
subjects, albeit in many cases the target values were not 
achieved. For subjects with DM and established CAD (very 
high-risk category) who have been on statin therapy, the target 
value for LDL-C (<1.8mmol/L) had not been achieved in 94%. 
Furthermore, a high proportion of the entire group had lipid 
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FIGURE 3: Distribution of LDL-C values in 126 subjects 
admitted with acute myocardial infarction, categorised 
by risk level (very high risk versus low-medium/high 
risk) and statin therapy (treated versus untreated). 
The horizontal black bars represent the target values 
of 3.0mmol/L for patients at low-moderate risk (the 
value for high-risk is more stringent at 2.6mmol/L, not 
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5.12 (1.34) 5.43 ( SD ± 1.56) 0.25 6.03 ( SD ± 1.53) 5.36 ( SD ± 1.63) 0.246
LDL-C (mmol/L) 3.27 ( SD ± 1.13) 3.45 ( SD ± 1.43) 0.64 4.13 ( SD ± 1.26) 3.33 ( SD ± 1.38) 0.484
HDL-C (mmol/L) 0.99 ( SD ± 0.32) 1.06 ( SD ± 0.32) 0.26 1.06 ( SD ± 0.18) 1.07 ( SD ± 0.31) 0.245
Triglycerides (mmol/L) 1.95 ( SD ± 1.29) 2.24 ( SD ± 1.25) 0.20 1.74 ( SD ± 0.94) 2.26 ( SD ± 1.23) 0.215
Non-HDL-C (mmol/L) 4.13 ( SD ± 1.22) 4.44 ( SD ± 1.54) 0.30 4.97 ( SD ± 1.55) 4.40 ( SD ± 1.62) 0.225
TC:HDL-C ratio 5.44 ( SD ± 1.46) 5.42 ( SD ± 1.73) 0.98 5.80 ( SD ± 1.63) 5.26 ( SD ± 1.70) 0.947
LDL-C:HDL-C ratio  3.46 ( SD ± 1.20) 3.50 ( SD ± 1.85) 0.87 4.00 ( SD ± 1.31) 3.29 ( SD ± 1.43) 0.907
Subjects with lipid profi le 
below target value
8 (16.3%) 8 (10.4%) 0.41 1 (8.3%) 7 (13.7%) 0.329
Subjects with 
hyperlipidaemia  
41 (83.7%) 69 (89.6%) 11 (91.7%) 44 (86.3%) 0.329
Type of infarct 0.009
NSTEMI 23 (47%) 54 (70%)
STEMI 26 (53%) 23 (30%)
TC = Total cholesterol, HDL-C = High-density lipoprotein cholesterol, LDL-C = Low-density lipoprotein cholesterol, NSTEMI = Non-ST elevation myocardial infarction,
STEMI = ST-elevation myocardial infarction, DM = Diabetes mellitus. *HbA1c values are unknown for 14 subjects (18.2%) with diabetes mellitus. **p value for significance of difference 













values which exceeded those recommended for their risk cate-
gory, irrespective of statin therapy, placing them at a higher 
risk of CAD. Subjects taking lipid-lowering therapy were less 
likely to experience a STEMI and more likely to present with 
NSTEMI. No patients were receiving fibrates or other lipid-
lowering agents, despite the apparent suboptimal response to 
statin therapy and high TG levels in 10 subjects. Lipid values in 
subjects with a previous AMI did not differ significantly from 
those with a first presentation of AMI, and were not more likely 
to have an LDL-C value within the range recommended for 
their risk category.
Atherosclerotic CVD is associated with a number of risk factors. 
Hyperlipidaemia, hypertension and cigarette smoking together, 
are associated with a 7-fold increase risk for ACS.(14) The mean 
number of risk factors in our subjects was 3.45, equating to 
a high-risk population for CAD. In other local studies, Masina, 
et al. reported smoking, hypertension and DM as being the 
most prevalent risk factors for CAD in the African community 
of South Africa, while Chetty and Ross, et al. reported smoking, 
DM and family history of CAD as prominent cardiovascular 
risk factors in the Indian population.(15,16) In our study, hyper-
lipidaemia was the most prevalent risk factor, with 87.3% of 
all cases having abnormal lipid profiles. We found no gender 
predisposition for hyperlipidaemia. Hypertension and DM were 
also frequently encountered. Despite an extensive national 
anti-smoking programme in place since 1993, including a com-
plete ban on tobacco advertising and the inclusion of health 
warnings on packaging, 71.8% of males in our study had a 
smoking history.
Most of our subjects were male. It is known that there is a 
gender difference in the rates of CAD, with men having a 40% 
higher risk of dying from any form of CAD than women.(17) 
Smoking was also found to be more prevalent in males than 
females – resulting in men having an added risk factor for 
CVD.(18,19) Additional determinants may be differences in expo-
sure to other risk factors and the cardio-protective effects of 
oestrogen in the female sub-population. A reduction in oestro-
gen production in post-menopausal women changes the lipid 
metabolism toward a more atherogenic form by increasing TC, 
LDL-cholesterol and triglyceride level, with a reduction in HDL 
cholesterol.(20) In our study, however, females presented with 
premature CAD more frequently than males, and a possible 
explanation for this lies in the observation that female subjects 
had a higher prevalence of other risk factors, including hyper-
tension and DM, as has also been shown in the Phoenix Lifestyle 
project.(21) 
The high incidence of DM in our subjects may be a major cause 
of secondary dyslipidaemia.(5) Subjects with type 2 DM have 
an increased risk of CAD, the risk increasing 2 - 3-fold for men 
and 3 - 5-fold for women. Patients with DM have a worse out-
come following AMI than normoglycaemic individuals.(22) Lipid 
disturbances are common in DM, and effective management of 
DM is associated with an improvement in lipid profile.(23,24) Since 
lipid disturbances contribute to the development of 
atherosclerosis and CAD, management of hyperlipidaemia in 
subjects with DM is crucial. Adequate management should 
result in lipid levels that are similar to non-diabetic patients. We 
demonstrated a high percentage of subjects with pre-existing 
DM. Females had a signif icantly higher prevalence of DM 
(72.9%), and HbA1c levels were significantly higher than those 
in males. Most subjects with DM had suboptimal glycated 
haemoglobin values, implying poor diabetic control; only 15.6% 
of subjects had glycated haemoglobin values at target. The 
association between DM and poor lipid profiles is well docu-
mented, and yet in our study we found no difference in mean 
lipoprotein values between the 2 groups. A previous South 
African study showed that 93.5% of diabetic subjects treated 
with lipid-lowering therapy did not reach lipid target values, 
and no signif icant relationship was found between HbA1c and 
any of the lipid parameters.(25) In our study, 15 of the subjects 
with diagnosed DM were not on statin therapy, and for those 
who were on statin therapy, a high number were not at treat-
ment target values for LDL-C – indicating an overall poor lipid 
control. Furthermore, an inappropriate diet, together with lack 
of exercise and obesity, may have contributed to the abnor-
mal lipid status, but these factors were not evaluated in this 
study. Though DM has been recognised as a complication of 
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On target (% 
of those on 
statin therapy)
4 (5.9%) 5 (41.7%) 9 (11.2%)
Subjects classified as very high risk are those with a history of previous acute coronary 
syndrome or diabetes mellitus. The low-medium and high-risk categories could not be 
distinguished owing to a lack of historical information. The subjects counted as “on 
target” are those whose LDL-C values fell below 1.8mmol/L if in the very-high-risk 
category, and below 3.0mmol/L if in the low-medium or high-risk categories. These 2 
categories could not be distinguished on the information available. The target level set 
for subjects at low-medium risk in terms of the South African Dyslipidaemia Guidelines 
Consensus Statement, is 3.0mmol/L.
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statin therapy itself, the incidence of this is thought to be 
extremely low, and the association between statin use and 
DM has not been shown to be causal.(26,27) We therefore 
believe that the high prevalence of DM in our study is a true 
reflection of its actual prevalence, and is not artificially increased 
by statin therapy.
LIMITATIONS
This is a retrospective chart audit at a single centre, with no 
control group. Our findings may be strengthened by expanding 
the study to include a larger population at multiple sites. The 
study focused on a number of risk factors, particularly hyper-
lipidaemia, but was not designed to provide data in detail for 
other risk factors such as obesity, hypertension, quantification of 
smoking exposure, and treatment compliance. We were unable 
to perform accurate risk stratification owing to lack of data. 
Angiography is not available at this hospital, and we were 
unable to correlate glycaemic and lipid control with extent of 
disease. Lack of information about prior statin dose prevented 
us from analysing more closely the relationship between statin 
therapy and lipid levels noted on admission. We did not collect 
information on other pre-existing therapy such as antiplatelet 
and anti-remodelling therapy. This was not part of the study as 
originally planned, and the extent of failure of secondary pro-
phylaxis in subjects with a previous AMI, only became apparent 
as results emerged.
Though the European Society of Cardiology guidelines suggest 
that a non-fasting lipogram is as predictive of risk as a fasting 
lipogram, there is evidence that the LDL-C value may be up to 
0.6 mmol/L lower in non-fasting than in fasting samples.(28) This 
may have led to our LDL-C values being slightly conservative, 
with an overall higher risk than would otherwise be inferred.
CONCLUSIONS
In conclusion, we  demonstrated a high prevalence of hyper-
lipidaemia in subjects presenting with an AMI. The subjects in 
the population studied demonstrated multiple risk factors. A 
major finding has been the very high prevalence of potentially 
modifiable risk factors, particularly hyperlipidaemia, DM, hyper-
tension and smoking. Subjects with DM have elevated glycated 
haemoglobin levels, and there is a high rate of hyperlipi-
daemia – with over 80% of subjects having LDL-C levels that 
exceed the SADGCS-recommended target levels, even when 
treated with statins. Our findings suggest that potentially modi-
fiable risk factors may have been inadequately addressed, 
indicating possible failures in both primary and secondary pro-
phylaxis. Glycated haemoglobin and lipid levels that are no 
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better in those with a previous AMI than in those with a first 
AMI, support our view that, in these subjects, secondary pro-
phylaxis has not resulted in optimal metabolic outcomes. 
RECOMMENDATIONS
Our findings support the need for the current national screen-
ing programme for DM and hypertension and we suggest that 
this be expanded to include screening for hyperlipidaemia. 
Strengthening primary healthcare to ensure adequate primary 
prevention of IHD by effective control of modifiable risk factors 
for CAD needs urgent attention as we have demonstrated 
this to be a problem in the subjects studied. Once identified, 
subjects need to be commenced on effective treatment, and 
be treated to target. In addition to pharmacotherapy, inter-
ventions are required to improve drug availability, adherence to 
medication, and to bring about lifestyle modifications includ-
ing  appropriate diet, regular exercise and smoking cessation. 
Though use of a combined pill (the “polypill”) consisting of 
aspirin, statin and antihypertensive has been reported as being 
associated with improved compliance,(29-33) a Cochrane review 
has suggested that the evidence is not as yet conclusive, and 
that further studies are necessary to establish its utility.(34) Many 
newer lipid-lowering agents are under development and a 
few, such as the proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitors, are now approved for use elsewhere, 
though not in South Africa.(35) Availability of alternate treatment 
for subjects unable to tolerate first line statin therapy may 
improve lipid control in these subjects.
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